Recent Company News

• 04:29 AM ET Apr 17, 2025
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 01:32 AM ET May 07, 2025
  

  bioMerieux downgraded to sector perform from outperform at RBC Capital Markets (€117.20, 0.00)

• 02:53 AM ET Mar 07, 2025
  

  StreetAccount Summary - European pre-market trading update

• 01:08 AM ET Apr 17, 2025
  

  bioMerieux reports Q1 sales €1.10B vs FactSet €1.08B [3 est, €1.05-1.10B]; confirms FY25 sales guidance and closely monitoring evolving tariff situation (€118.30, 0.00)

• 03:33 AM ET Apr 07, 2025
  

  bioMerieux downgraded to hold from buy at TPICAP Midcap (pre-open) (€109.80, -4.90)

• 01:06 AM ET Apr 07, 2025
  

  bioMerieux obtains CE-marking of LUMED APSS, an advanced clinical decision support system designed to enhance antimicrobial stewardship programs and improve patient outcomes (€114.70, 0.00)

• 02:04 AM ET Mar 18, 2025
  

  bioMérieux receives FDA 510(k) Clearance for its VITEK COMPACT PRO, a new ID/AST system to fight against antimicrobial resistance (€114.90, 0.00)

• 04:28 AM ET Mar 07, 2025
  

  StreetAccount Summary: EU stocks reaching new 52-week highs/lows (109 total)